Yan-Cheng Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yan-Cheng Liu has a total of 171 co-authors. Here are the top co-authors by number of shared publications:
- Hong Liang
Key Laboratory for Chemistry and Molecular Engineering of Medicinal Resources (Ministry of Education of China), Guangxi Key Laboratory of Chemistry and Molecular Engineering of Medicinal Resources, University Engineering Research Center for Chemistry of Characteristic Medicinal Resources (Guangxi), School of Chemistry and Pharmaceutical Sciences, Guangxi Normal University, Guilin 541004, China
24 shared publications Hong Liang
School of Chemistry and Pharmaceutical Sciences, Key Laboratory for Chemistry and Molecular Engineering of Medicinal Resources (Ministry of Education of China), Guangxi Key Laboratory of Chemistry and Molecular Engineering of Medicinal Resources, University Engineering Research Center for Chemistry of Characteristic Medicinal Resources (Guangxi), Guangxi Normal University, No. 15, Yucai Road, Guilin 541004, China
16 shared publications- Zhen-Feng Chen
Key Laboratory for Chemistry and Molecular Engineering of Medicinal Resources (Ministry of Education of China), Guangxi Key Laboratory of Chemistry and Molecular Engineering of Medicinal Resources, School of Chemistry and Pharmaceutical Sciences Guangxi Normal University Guilin 541004 China
16 shared publications - Qi-Pin Qin
Guangxi Key Lab of Agricultural Resources Chemistry and Biotechnology, College of Chemistry and Food Science, Yulin Normal University, 1303 Jiaoyudong Road, Yulin 537000, PR China; State Key Laboratory for the Chemistry and Molecular Engineering of Medicinal Resources, School of Chemistry and Pharmacy, Guangxi Normal University, 15 Yucai Road, Guilin, 541004, PR China
14 shared publications Rui-Xue Liu
14 shared publicationsZhen-Feng Chen
School of Chemistry & Pharmaceutical Sciences, State Key Laboratory for the Chemistry and Molecular Engineering of Medicinal Resources, Guangxi Normal University, Guilin 541004, PR China
9 shared publications
Latest Publications
- 13 November 2026
- Published by American Chemical Society (ACS) in ACS Applied Bio Materials
A Photothermal/Chemodynamic Combined Therapy Nanoplatform AuNRs@FQ Capable of Generating Reactive Oxygen Species and Inhibiting Tumors
The advancement of catalytic therapy is often limited by the insufficient reaction rates, and the treatment efficacy is less than ideal. It is necessary to improve the kinetics of catalytic reactions to enhance the performance of the therapy. Here, we reported a nanoplatform AuNRs@FQ that utilized the photothermal heating to boost the catalytic activity while simultaneously employing photothermal treatment (PTT) and chemodynamic therapy (CDT) for breast cancer intervention. In this system, the gold nanorods (AuNRs) with the excellent near-infrared-II (NIR-II) photothermal conversion are covered by the Fe3+–quercetin (FQ) metal–phenolic framework (MPN). The MPN disintegrates in a pH-sensitive manner within the mildly acidic tumor microenvironment, concurrently releasing Fe3+ ions and quercetin (Que). The released Fe3+ can scavenge the intracellular glutathione (GSH) to disrupt the cellular antioxidant defense system and is reduced to Fe2+. Subsequently, Fe2+ catalyzes the decomposition of hydrogen peroxide (H2O2) to generate highly reactive oxygen species (ROS), specifically hydroxyl radicals (·OH), via the Fenton reaction. As a natural chemotherapeutic compound, Que also increases the concentration of intracellular ROS, thus enhancing the cytotoxic effect of CDT. The AuNR nanomaterial can produce the quick production of the localized elevated temperature when irradiated by 1064 nm laser light, which improves the catalytic performance and the CDT result and delivers the effective PTT. Both in vitro and in vivo, it was also shown that AuNRs@FQ remarkably suppressed the growth of the breast cancer cells and the development of the tumor. This study presents a NIR-II photothermal amplification approach using the MPN-mediated CDT and combining the photothermal and catalytic therapies to greatly boost the ROS generation and to accomplish a potent combined treatment.
- 13 November 2026
- Published by American Chemical Society (ACS) in ACS Applied Bio Materials
A Photothermal/Chemodynamic Combined Therapy Nanoplatform AuNRs@FQ Capable of Generating Reactive Oxygen Species and Inhibiting Tumors
The advancement of catalytic therapy is often limited by the insufficient reaction rates, and the treatment efficacy is less than ideal. It is necessary to improve the kinetics of catalytic reactions to enhance the performance of the therapy. Here, we reported a nanoplatform AuNRs@FQ that utilized the photothermal heating to boost the catalytic activity while simultaneously employing photothermal treatment (PTT) and chemodynamic therapy (CDT) for breast cancer intervention. In this system, the gold nanorods (AuNRs) with the excellent near-infrared-II (NIR-II) photothermal conversion are covered by the Fe3+–quercetin (FQ) metal–phenolic framework (MPN). The MPN disintegrates in a pH-sensitive manner within the mildly acidic tumor microenvironment, concurrently releasing Fe3+ ions and quercetin (Que). The released Fe3+ can scavenge the intracellular glutathione (GSH) to disrupt the cellular antioxidant defense system and is reduced to Fe2+. Subsequently, Fe2+ catalyzes the decomposition of hydrogen peroxide (H2O2) to generate highly reactive oxygen species (ROS), specifically hydroxyl radicals (·OH), via the Fenton reaction. As a natural chemotherapeutic compound, Que also increases the concentration of intracellular ROS, thus enhancing the cytotoxic effect of CDT. The AuNR nanomaterial can produce the quick production of the localized elevated temperature when irradiated by 1064 nm laser light, which improves the catalytic performance and the CDT result and delivers the effective PTT. Both in vitro and in vivo, it was also shown that AuNRs@FQ remarkably suppressed the growth of the breast cancer cells and the development of the tumor. This study presents a NIR-II photothermal amplification approach using the MPN-mediated CDT and combining the photothermal and catalytic therapies to greatly boost the ROS generation and to accomplish a potent combined treatment.
- 20 October 2026
- Published by Springer Nature in Microchimica Acta
- Vol. 193 (11) , 744
A tumor microenvironment-activatable CuS@TF nanosystem with intrinsic multi-nanozyme properties for NIR-II photoacoustic imaging-guided synergistic PTT/CDT
- 20 October 2026
- Published by Springer Nature in Microchimica Acta
- Vol. 193 (11) , 744
A tumor microenvironment-activatable CuS@TF nanosystem with intrinsic multi-nanozyme properties for NIR-II photoacoustic imaging-guided synergistic PTT/CDT
- 11 June 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (12) , 14902-14920
Pt(IV) Complexes Incorporating CDC25A/NF-κB Dual Inhibitory 1,4-Naphthoquinone Derivatives Trigger Multimodal Cell Death in A2780 Ovarian Cancer Cells
This work presents a novel, promising, and efficient strategy to develop potential Pt(IV) prodrugs for cancer chemotherapy while to simultaneously overcome the ″undruggability″ of CDC25A. New series of Pt(IV) complexes (Pt5-Pt13) bearing 1,4-naphthoquinone (NQ, a natural active skeleton) derivatives (c1-c3) as potential dual CDC25A/NF-κB inhibitory ligands were synthesized and characterized. Their in vitro and in vivo anticancer activities were subsequently evaluated. Mechanistic investigations revealed that Pt6, the most potent candidate with ligand c2, effectively depleted CDC25A levels in A2780 cancer cells through a synergistic effect mediated by DNA damage. Thus, Pt6 triggered multimodal anticancer mechanisms, which included reactive oxygen species/endoplasmic reticulum stress-mediated mitochondrial apoptotic pathway, DNA damage coupled with S-phase cell cycle arrest, and autophagy-dependent ferroptosis. In A2780 xenograft models, Pt6 administrated with a dosage of 8 mg/kg manifested superior tumor growth inhibition than both cisplatin and "cisplatin + c2" combination, along with satisfying low toxicity.
- 11 June 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (12) , 14902-14920
Pt(IV) Complexes Incorporating CDC25A/NF-κB Dual Inhibitory 1,4-Naphthoquinone Derivatives Trigger Multimodal Cell Death in A2780 Ovarian Cancer Cells
This work presents a novel, promising, and efficient strategy to develop potential Pt(IV) prodrugs for cancer chemotherapy while to simultaneously overcome the ″undruggability″ of CDC25A. New series of Pt(IV) complexes (Pt5-Pt13) bearing 1,4-naphthoquinone (NQ, a natural active skeleton) derivatives (c1-c3) as potential dual CDC25A/NF-κB inhibitory ligands were synthesized and characterized. Their in vitro and in vivo anticancer activities were subsequently evaluated. Mechanistic investigations revealed that Pt6, the most potent candidate with ligand c2, effectively depleted CDC25A levels in A2780 cancer cells through a synergistic effect mediated by DNA damage. Thus, Pt6 triggered multimodal anticancer mechanisms, which included reactive oxygen species/endoplasmic reticulum stress-mediated mitochondrial apoptotic pathway, DNA damage coupled with S-phase cell cycle arrest, and autophagy-dependent ferroptosis. In A2780 xenograft models, Pt6 administrated with a dosage of 8 mg/kg manifested superior tumor growth inhibition than both cisplatin and "cisplatin + c2" combination, along with satisfying low toxicity.
- 21 April 2026
- Published by Elsevier in Bioorganic Chemistry
- Vol. 177, 109906
Co-crystals of berberine with two natural polyphenols: synthesis, crystal structure and bacteriostasis on aquatic pathogens
- 21 April 2026
- Published by Elsevier in Bioorganic Chemistry
- Vol. 177, 109906
Co-crystals of berberine with two natural polyphenols: synthesis, crystal structure and bacteriostasis on aquatic pathogens
- 13 March 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (6) , 6835-6853
The First Multimodal Anticancer Manganese(II) Complex of an Asymmetric Anthrahydrazone Triggers Apoptosis, Autophagy and Ferroptosis
A new nonsymmetric anthrahydrazone ligand (AAIH) was designed and synthesized, affording novel manganese(II) and cobalt(II) complexes, AAIH-Mn and AAIH-Co. Both complexes crystallized in the same centrosymmetric dinuclear coordination mode, however, AAIH-Mn exhibited much higher in vitro cytotoxicity (IC50 = 1.64 μM against MGC-803 cells) than AAIH-Co (IC50 = 10.05 μM) and AAIH (IC50 = 18.82 μM), signifying the importance of the Mn(II) center. Furthermore, AAIH-Mn exerted anticancer activity via multiple pathways: S-phase cell cycle arrest, cell apoptosis, autophagy and notably, the emerging process of ferroptosis. AAIH-Mn also effectively inhibited 56% of tumor growth in vivo on MGC-803 xenografts at 16 mg/kg, without causing obvious toxicity. Low toxicity was further supported by zebrafish models, along with its anti-inflammatory activity and low cardiotoxicity. As the first Mn(II) complex inducing ferroptosis, AAIH-Mn provides a valuable example of a low-toxicity metal center to generate highly cytotoxic nonplatinum anticancer complex.
- 13 March 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (6) , 6835-6853
The First Multimodal Anticancer Manganese(II) Complex of an Asymmetric Anthrahydrazone Triggers Apoptosis, Autophagy and Ferroptosis
A new nonsymmetric anthrahydrazone ligand (AAIH) was designed and synthesized, affording novel manganese(II) and cobalt(II) complexes, AAIH-Mn and AAIH-Co. Both complexes crystallized in the same centrosymmetric dinuclear coordination mode, however, AAIH-Mn exhibited much higher in vitro cytotoxicity (IC50 = 1.64 μM against MGC-803 cells) than AAIH-Co (IC50 = 10.05 μM) and AAIH (IC50 = 18.82 μM), signifying the importance of the Mn(II) center. Furthermore, AAIH-Mn exerted anticancer activity via multiple pathways: S-phase cell cycle arrest, cell apoptosis, autophagy and notably, the emerging process of ferroptosis. AAIH-Mn also effectively inhibited 56% of tumor growth in vivo on MGC-803 xenografts at 16 mg/kg, without causing obvious toxicity. Low toxicity was further supported by zebrafish models, along with its anti-inflammatory activity and low cardiotoxicity. As the first Mn(II) complex inducing ferroptosis, AAIH-Mn provides a valuable example of a low-toxicity metal center to generate highly cytotoxic nonplatinum anticancer complex.